In the PROSPER study, median overall survival was significantly longer among enzalutamide-treated patients compared with placebo recipients (67.0 vs 56.3 months).
After receiving intense hormone therapy prior to radical prostatectomy, one-fifth of men with high-risk localized prostate cancer had no tumor or residual tumor smaller than 5 mm following surgery, a study found.
Almost 40% of men with metastatic castration-resistant prostate cancer experience radiographic disease progression while on second-generation hormone therapy despite stable or declining PSA, a study found.
In the phase 3 HERO trial, more relugolix than leuprolide recipients achieved sustained testosterone suppression over 48 weeks: 96.7% vs 88.8%, respectively.
Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.
Wide regional variation seen for availability of telehealth outpatient visits, tele-ICU services.
22% of patients critically ill; older age, chronic cardiac disease linked to higher in-hospital mortality.
New findings suggest that the HSD3B1 genotype can be used to risk stratify white men with low-volume metastatic prostate cancer.
Rates of regional- and distant-stage prostate cancer increasing in the US among men older than 50 years.
The FDA has approved Lynparza® (olaparib; AstraZeneca and Merck) for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone.